Sage advice: psychiatric drug development is tough | Evaluate
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Proper Résumés - Résumés that stand out and breakthrough applicant tracking systems. | Facebook
Sage Therapeutics Could Be In For A Depressing FDA Review (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Business Wire
SY Investing on X: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total
Rx Product News: April 2023
SEC Filing | Sage Therapeutics, Inc.
Sage Announces Results of FDA Breakthrough Therapy Meeting – ISPE Boston
Sage Therapeutics surges 70% after depression drug breakthrough
Zulresso: the world's first post-partum depression drug - Pharmaceutical Technology
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders | Business Wire
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
FDA Provides Expedited Path Forward For Sage's Depression Treatment SAGE-217 | BioSpace
Sage Therapeutics Looks to File NDA for Postpartum Depression Treatment Later This Year | BioSpace
